Public Interest Litigation in Delhi High Court seeks to ban on sex-selective surgeries
By Amiya Kumar Kushwaha,
Asian News International
| 08. 16. 2021
Photo by Sadasiv Swain on Flickr
A public interest litigation (PIL) was filed in the Delhi High Court seeking to declare a ban on medically unnecessary, sex-selective surgeries on intersex infants and children except in cases of life-threatening situations in the national capital.
The public interest litigation was filed by Srishti Madurai Educational Research Foundation through advocates Robin Raju, Yash Prakash and Deepa Joseph.
The petitioner organisation claimed to be at the forefront in spreading awareness about the necessity to ban sex-selective surgeries on infants with intersex traits.
The petitioner said that the Delhi Commission for Protection of Child Rights (DCPCR) in January 2021 had given a considered opinion that the Respondent Delhi government and its state Ministry of Health and Family Welfare should declare a ban on medically unnecessary, sex-selective surgeries on intersex infants and children except in cases of life-threatening situations but no decision has been taken on the opinion of DCPCR.
"That the issue of sex-selective surgeries or medically unnecessary normalizing surgeries has a long lasting drastic psychological impact on the minds of intersex people and deters...
Related Articles
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...
By Ben Fidler and Ned Pagliarulo, Biopharma Dive | 07.21.2025
One month ago, a 51-year-old man treated in a clinical trial with an experimental gene therapy became dangerously sick. The developer of that treatment, Sarepta Therapeutics, informed the Food and Drug Administration his case could be life-threatening.
The man died...
By Pat Duggins, Alabama Public Radio | 06.27.2025
PAT DUGGINS-- If I were to say, ‘man, have you seen the price of eggs these days?’ You're probably thinking, Oh, he's talking about inflation and the price of groceries and how it became an issue in the presidential race...